 |
|
Feb 10
2005
Non Client
|
E M P I R E
R E L A T I O N S
G R O U P
P R E S E N T S T H E
|
 |
Gold Star Report
|
|
|
Amylin Pharmaceuticals, Inc.
|
|
Overview
"Learn from yesterday, live for today, hope for tomorrow."
Anon
This quote may be the thought behind many who work on finding cures and drugs to help those afflicted by various diseases. One disease in particular that afflicts tens of millions, sometimes unknowingly, is Diabetes. It’s estimated by the International Diabetes Foundation that 194 million worldwide suffer from this disease. In the U.S., it’s estimated that 6% of the population has Diabetes. Of those affected, the C.D.C. states that over 5 million Americans may not be aware that they have the disease. In children and young adults, one in 400 to 500 are afflicted. The troubling part is that between 1980-2002, the number of cases has doubled in the U.S. alone.
Diabetes is a disorder of the metabolism when the body does not produce or properly use insulin. Insulin is a hormone secreted by the pancreas that converts sugar, starch and other foods into the energy that is used by the body for daily living. Another hormone secreted by the pancreas is amylin which works with insulin in the body.
There are several forms of diabetes: Type 1, Type 2 and Pre-Diabetes. Type 1 is when the body fails to produce insulin or produces very little. Those who suffer from this form must take insulin injections. Estimates are that 5-10% of Americans are affected by this form of Diabetes. Type 2 Diabetes occurs when the body does not produce enough insulin or the body fails to properly metabolize the insulin. This is the most common form of Diabetes and is often linked to obesity. While Diabetes onset can come at any age, Type 2 tends to affect mostly adults.
The long- and short-term effects of diabetes include blurred vision, fatigue, unusual thirst, heart attacks and stroke. Diabetes can also create permanent damage to the kidneys, eyes, feet, nerves and blood vessels among others. This GoldStar looks at Amylin Pharmaceuticals, Inc. which has been working to find new drugs to help with this disease and other metabolic diseases since 1987. The Company has its headquarters in San Diego, California. Amylin Pharmaceuticals, Inc. trades on the NASDAQ exchange under the symbol AMLN. The company has 5 drugs in its pipeline at various stages of the FDA approval process, and one under evaluation. Of the drugs in the pipeline, Exenatide and SYMLIN are both first-in-class drugs, and have finished Phase III. Response from the FDA is expected respectively on April 2005 and March 2005. Of the other drugs, 2 are in Phase II and one is in Phase I as of 2004. Since 2002, the Company has partnered with Eli Lilly to develop Exenatide for U.S. and worldwide distribution.
Before making an investment in this security, we advice that you seek consultation with a qualified investment professional.Please read the disclaimer printed in this page.
Products
Both of the lead drug candidates for the Company have finished Phase III of the FDA approval process. They are currently are being reviewed.
Exenatide - A first-in-class drug in the new class called incretin mimetics, to treat individuals with Type 2 diabetes. According to a 6 month clinical study completed in July 2004, Exenatide provided similar glucose control as compared to insulin glucargine and provided a weight loss vs weight gain for insulin glucargine. Eli Lilly and Co has partnered with the Company on this drug since September 2002. Response from the FDA is expected by April 2005.
SYMLIN - A first-in-class drug candidate, a synthetic human amylin (a hormone co-secreted with insulin by the pancreas) for individuals with Type 1 diabetes and those with Type 2 that require insulin. Response from the FDA is expected by March 2005.
The Company also has 4 additional candidates at various stages of the FDA approval process.
|
|
In the News
Febuary 7, 2005 - The Company will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, February 10, 2005 at 9:30 a.m. ET in New York. Daniel Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
January 27, 2005 - The Company announced the exercise by its underwriters of an over-allotment option to purchase 1,200,000 shares of common stock associated with its follow-on stock offering which priced on January 20, 2005. Including the over-allotment shares, the offering will total 9,200,000 shares at $22.00 per share, resulting in expected net proceeds to the company of approximately $190.5 million.
January 21, 2005 - The Company will be presenting at the Piper Jaffray Health Care Conference on Wednesday, January 26, 2005 at 10:30 a.m. ET in New York. Mark Foletta, VP, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
January 21, 2005 - The Company announced a public offering of 8.0 million shares of common stock at a price of $22.00 per share. The underwriters have a 30-day option to purchase up to 1.2 million additional shares of common stock from the company to cover over-allotments.
January 5, 2005 - Ginger L. Graham, President and Chief Executive Officer of Amylin Pharmaceuticals will be providing a corporate overview which will include a review of the company's development programs.
December 5, 2004 - The Company presented an update on its clinical development programs at a reception webcast from San Diego, CA. Included in the presentation were new data from its pramlintide (AC137) obesity program and details of a Phase 2 study recently initiated in its AC2592 development program for congestive heart failure. The successful completion of the AC137 study and initiation of the AC2592 study mark the achievement of all of the Company's stated development milestones for 2004.
|
|
About Us
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, cardiovascular disease and other metabolic diseases.
Key Points
- Has 2 drug candidates in post-Phase III, 2 in Phase II.
- Total assets of 367 million dollars including 101 million in cash.
- Partnered with Eli Lilly and Co, for the Exenatide drug.
- Symlin is the first drug candidate in 80 years other than insulin and its analogues to complete Phase III trials indicated for glucose control in Type 1 Diabetes.
- Exenatide is first-in-class and part of new class of drugs called incretin mimetics for Type 2
|
|
|
Key Information
|
|
Current Stock Price
|
$22.48
|
|
52 Week Low
|
$16.48
|
|
52 Week High
|
$26.80
|
|
Stock Symbol
|
AMLN
|
|
Exchange
|
NASDAQ
|
|
Shares Outstanding
|
94,355,895
|
|
Financial Information
|
|
Revenues
|
$27.64 million (9/30/04)
|
|
Total Cash and equivalents
|
$336.9 million (9/30/04)
|
|
Total Assets
|
$367 million
|
|
Convertabile Notes (senior)
|
$375 million
|
|
|
Management
|
|
Joseph Cook, Jr |
Chairman |
|
Ginger Graham |
Pres, CEO, Director |
|
Mark Foletta |
CFO, VP-Fin. |
|
Daniel Bradbury |
COO|
Julia Brown |
Exec. VP |
Headquarters:
Amylin Pharmaceuticals, Inc.
9360 Tower Centre Drive Ste 110
San Diego Ca 92121
(P) (858) 5522200
Website: www.amylin.com
All dollar figures are in U.S. dollars. To obtain copies, please contact Kenneth Maciora at Empire Relations Group Inc. at (516)750-9719.
Download/Print PDF
of this Gold Star Report
| |
|
Disclaimer
This Gold Star Report™ contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties, and other factors, not under the Company's control, which may cause actual results, performance, or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward looking statements. This Profile is prepared for general information only. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this profile. The information and statistical data contained within have been obtained from sources believed to be reliable but in no way are warranted as to accuracy or completeness. This is not a solicitation of any offer to buy or sell. Empire Relations Group Inc., its affiliates, directors, officers, employees and employee benefit programs do not maintain an equity position, either long or short, in this security at this time. Empire Relations Group Inc. has not received any compensation for the production of this Gold Star Report Copyright © 2005. Empire Relations Group Inc. All rights reserved.
|
|
Gold Star Report
|
|
|
|
|
